Cardiovascular disease remains the leading cause of death, disability, and healthcare economic burden worldwide and as such remains the leading population health challenge of our age. Management of LDL-C or “bad cholesterol” is among the most cost-effective and impactful preventative interventions. While statins have had an enormous impact, tens of millions of patients on maximally tolerated statin therapy fail to reach LDL-C targets each year leading to millions of preventable cardiovascular events. Recently offered injectable add-on therapies have thus far failed to scale. New Amsterdam Pharmaceuticals is developing a tablet which has shown a 50% reduction in LDL-C on top of statins in mid-stage clinical trials.